who had met at Eli Lilly, were working on synthetic versions of glucagon to treat sudden drops in blood glucose when they unexpectedly found long-term dosing caused weight-loss in obese mice. Since GLP-1 and GIP are closely related, they thought it might be possible to target both receptors...